Resolution Therapeutics

CompanyUnited Kingdom

Resolution Therapeutics develops one asset, in phase 2 (RTX001 in end-stage liver disease). Mostly cell therapy; based in the United Kingdom.

1
Asset
Furthest stage
Phase 2
Raised
£88.1M + $85M
1
Trial
1
Signal

Pipeline

1
  • RTX001

    Engineered immune cells intended to treat end-stage liver disease.

    Phase 2, Cell therapy, end-stage liver disease, cirrhosis (Phase 1)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Funding rounds and grants10
  • People6
  • Signals2
  • Similar companies6

Intelligence